Skip to content
Search

Latest Stories

Submit Guest Post

Young British Muslims gather in Surrey for national Ijtema

Young British Muslims gather in Surrey for national Ijtema

Young British Muslims gather in Surrey for national Ijtema

The Ahmadiyya Muslim Youth Association UK (MKA UK), one of Britain’s oldest and largest Muslim youth organisations, successfully hosted its annual National Ijtema 2025 from 19–21 September at Hook Lane, Puttenham, Guildford.

More than 6,000 young British Muslims from across the country attended the three-day gathering, which combined academic competitions, sports, discussions, and faith-inspiring talks. The event reaffirmed MKA UK’s commitment to serving Britain and humanity through charitable initiatives including blood drives, food donations, and community projects.


The Ijtema highlighted Islam’s values of peace, loyalty, and service to one’s country, offering young people a supportive platform to address questions of faith and identity.

The highlight of the event was the keynote address by His Holiness Mirza Masroor Ahmad, Head of the worldwide Ahmadiyya Muslim Community, delivered on the final day and broadcast globally.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

cancer treatment

The NHS availability announced in September 2026 applies to eligible patients in England. The treatment has already been available in Scotland for more than two years.

What is Enhertu and how could the new NHS breast cancer treatment help patients?

Highlights:
  • Enhertu is a targeted treatment for certain HER2-low breast cancers.
  • It is available for around 1,000 women in England.
  • The drug can extend survival compared with chemotherapy.
  • NICE initially rejected widespread NHS use in 2024.
  • The decision was reversed after a commercial agreement was reached.

Breast cancer treatment continues to evolve as researchers develop therapies aimed at specific characteristics of cancer cells. One such treatment is Enhertu, which has now become available on the NHS in England for people with a particular type of advanced breast cancer.

The treatment is intended for patients with HER2-low breast cancer that cannot be removed through surgery or has spread to other parts of the body. This is known as metastatic breast cancer. According to the latest announcement, around 1,000 women in England will be eligible for the treatment.

Keep ReadingShow less